Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study

被引：0
|
作者：
Xueli Nan
Chao Xie
Qingqing Zhu
Jianjun Zhang
Shuai Fu
Xiao Han
Qiujing Zhang
Baohui Han
Jie Liu
机构：
[1] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Oncology
[2] Wu Di People Hospital,Department of Oncology
[3] Shandong Cancer Hospital and Institute,School of Medicine and Life Sciences
[4] University of Ji’nan-Shandong Academy of Medical Sciences,Department of Pulmonary Medicine
[5] Shanghai Chest Hospital,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Non-small-cell lung cancer; Anlotinib; Adverse event; Clinical marker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1492 / 1498
页数：6
相关论文
共 50 条
  • [1] Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study
    Nan, Xueli
    Xie, Chao
    Zhu, Qingqing
    Zhang, Jianjun
    Fu, Shuai
    Han, Xiao
    Zhang, Qiujing
    Han, Baohui
    Liu, Jie
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (08) : 1492 - 1498
  • [2] Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303
    Si, Xiaoyan
    Zhang, Li
    Wang, Hanping
    Zhang, Xiaotong
    Wang, Mengzhao
    Han, Baohui
    Li, Kai
    Wang, Qiming
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    Shi, Yuankai
    Chen, Weiqiang
    Wang, Xiuwen
    Luo, Yi
    Nan, Kejun
    Jin, Faguang
    THORACIC CANCER, 2019, 10 (03) : 551 - 556
  • [3] NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Brahmer, Julie R.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Antonia, Scott J.
    Rizvi, Naiyer A.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, Stephen
    Snzol, Mario
    Harbison, Christopher T.
    Kollia, Gerogia D.
    Gupta, Ashok
    Gettinger, Scott N.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 157 - 157
  • [4] Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
    Cheng, Ying
    Han, Baohui
    Li, Kai
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    He, Jianxing
    Shi, Yuankai
    Chen, Weiqiang
    Wang, Xiuwen
    Luo, Yi
    Nan, Kejun
    Jin, Faguang
    Li, Baolan
    Zhu, Jing
    CANCER MEDICINE, 2020, 9 (08): : 2621 - 2630
  • [5] CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer: Analysis on ALTER-0303 study
    Liu, Zhujun
    Wang, Jing
    Meng, Zhaoting
    Wang, Xinyue
    Zhang, Cuicui
    Qin, Tingting
    Chen, Jinliang
    Jiang, Xiangli
    Wang, Liuchun
    Lin, Li
    Zhang, Xiaoling
    Chen, Peng
    Huang, Chun
    Jiang, Richeng
    Li, Kai
    CANCER MEDICINE, 2018, 7 (07): : 3011 - 3021
  • [6] Effect of Anlotinib in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial
    Wang, Q.
    Cheng, Y.
    Li, K.
    Shi, J.
    Han, B.
    Wu, L.
    Chen, G.
    He, J.
    Wang, J.
    Qin, H.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S211 - S211
  • [7] The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial
    Wang, Lili
    He, Zhen
    Yang, Sen
    Tang, Hong
    Wu, Yufeng
    Li, Shaomei
    Han, Baohui
    Li, Kai
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Chen, Weiqiang
    Luo, Yi
    Wu, Lin
    Wang, Xiuwen
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    Sun, Yan
    Wang, Qiming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 575 - +
  • [8] The efficacy of anlotinib in squamous cell carcinoma (SCC) patients with or without hypertension in ALTER0303: Anlotinib as a third-line therapy in patients with advanced non-small cell lung cancer (NSCLC).
    Shi, Jianhua
    Han, Baohui
    Li, Kai
    Wang, Qiming
    Zhang, Li
    Wang Zhe-Hai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Chen, Weiqiang
    Luo, Yi
    Wu, Lin
    Wang, Xiuwen
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
    Han, Baohui
    Li, Kai
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Zhao, Yizhuo
    Yu, Hao
    Zhao, Yang
    Chen, Weiqiang
    Luo, Yi
    Wu, Lin
    Wang, Xiuwen
    Pirker, Robert
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    Sun, Yan
    JAMA ONCOLOGY, 2018, 4 (11) : 1569 - 1575
  • [10] The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study
    Zhao, Yizhuo
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Chen, Weiqiang
    Luo, Yi
    Wu, Lin
    Wang, Xiuwen
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    Yamaguchi, Fumihiro
    Breadner, Daniel
    Nagano, Tatsuya
    Tanaka, Fumihiro
    Husain, Hatim
    Li, Kai
    Han, Baohui
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (05) : 776 - +
12345